145.18
-1.74 (-1.18%)
Penutupan Terdahulu | 146.92 |
Buka | 147.29 |
Jumlah Dagangan | 515,537 |
Purata Dagangan (3B) | 530,250 |
Modal Pasaran | 8,133,956,096 |
Harga / Pendapatan (P/E Ke hadapan) | 90.91 |
Harga / Jualan (P/S) | 12.77 |
Harga / Buku (P/B) | 4.06 |
Julat 52 Minggu | |
Tarikh Pendapatan | 20 Feb 2025 |
Margin Keuntungan | -1.28% |
Margin Operasi (TTM) | -3.02% |
EPS Cair (TTM) | -0.030 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 9.70% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | -83.40% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 33.35% |
Nisbah Semasa (MRQ) | 10.44 |
Aliran Tunai Operasi (OCF TTM) | 165.28 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 138.31 M |
Pulangan Atas Aset (ROA TTM) | 0.60% |
Pulangan Atas Ekuiti (ROE TTM) | -0.40% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
Medical Instruments & Supplies (Global) | Bercampur | Bercampur | |
Stok | Repligen Corporation | Menaik | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 1.0 |
Osilator Teknikal | -0.5 |
Purata | 1.38 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
|
Sektor | Healthcare |
Industri | Medical Instruments & Supplies |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 7.23% |
% Dimiliki oleh Institusi | 101.96% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Harding Loevner Lp | 30 Sep 2024 | 916,142 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 180.00 (HC Wainwright & Co., 23.98%) | Beli |
Median | 172.50 (18.82%) | |
Rendah | 165.00 (Canaccord Genuity, 13.65%) | Pegang |
Purata | 172.50 (18.82%) | |
Jumlah | 1 Beli, 1 Pegang | |
Harga Purata @ Panggilan | 163.02 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 23 Jan 2025 | 180.00 (23.98%) | Beli | 167.90 |
Canaccord Genuity | 17 Dec 2024 | 165.00 (13.65%) | Pegang | 158.14 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
11 Feb 2025 | Pengumuman | Repligen to Report Fourth Quarter and Full Year 2024 Financial Results |
07 Jan 2025 | Pengumuman | Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference |
06 Jan 2025 | Pengumuman | Repligen Launches the CTech™ SoloVPE® PLUS System |
16 Dec 2024 | Pengumuman | BioLife Solutions Appoints Tony J. Hunt to its Board of Directors |
12 Dec 2024 | Pengumuman | Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report |
09 Dec 2024 | Pengumuman | Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |